RE:Today’s News3 points jumped out for me today;
1. Accelerated approval timing (Kirk) enrollment over 18 month, plus 6 month study. That means 24 month until decision for accel. approval? So we are talking middle of 2027
2. That's also mentioned by Christoph D. About market size, again 2027 mentioned for approval, with a revenue potential of 4 BN by 2030.
3. Cash is 19.6 Mio (Kirk) but total expenditure (my guess) will be close to double for 1 year. So the financing question is completely open! Part finding thru partners or the big ,present pharmas like Pfizer and Roche seemed to be hinted at, but......